Bridgepoint Is to Acquire RoC Skincare


PARIS – Bridgepoint is set to acquire RoC Skincare, the French dermatological brand launched in 1957.

The undisclosed investment is being made through Bridgepoint Europe VII, Bridgepoint’s fund centered on investing in mid-market growth businesses. Gryphon Investors, RoC’s current backer, is to sell its majority stake in the brand to Bridgepoint as part of the transaction.

The deal is expected to close in February.

Dermatological skin care brands are in the scopes of investors today, as the segment’s business has seen significant growth over the past few years.

“The dermocosmetic facial skin care market in the U.S. and Europe is set to continue to grow ahead of the broader skin care space, a trend mirrored in products for ageing skin,” said Bridgepoint in a statement. 

“RoC, uniquely positioned as the best clinically proven specialist for aging skin conditions, has the potential to capture an even larger market share across geographies,” it said.

Bridgepoint intends to support RoC’s further growth acceleration in European markets and particularly in France.

“With Bridgepoint’s support, RoC is poised to accelerate growth in Europe and beyond, strengthen its online presence and expand its product offering,” said Fabrice Turcq, a partner at Bridgepoint.

RoC, which was founded by Jean-Charles Lissarrague, is among the biggest independent skin care brands worldwide, according to Bridgepoint. It said RoC is highly innovative, being  the first to launch hypoallergenic skin care products, broad-spectrum UV protection and stabilized Retinol products.

The brand is sold around the world, including in the U.S., Canada, France, the U.K., Continental Europe, Australia and China.

Gryphon Investors purchased RoC from Johnson & Johnson in 2020. Bridgepoint said that since then, the brand has generated significant organic growth. In the period, its sales increased 70 percent.

Bridgepoint’s other investments in the dermatology arena include HTL, a producer of high-quality hyaluronic acid, and Vivacy, a global personal health care company.

For the RoC acquisition, Bridgepoint’s advisers were Jeffries, Latham & Watkins, BCG, EY, ERM and Marsh.



Source link

About The Author

Scroll to Top